A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor–Positive Breast Cancer
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Purpose: SRC-family kinases (SFK) are involved in numerous oncogenic signaling pathways. A phase 2 trial of dasatinib, a potent oral tyrosine kinase inhibitor of SFKs, was carried out in patients with human epidermal growth factor receptor 2–positive (HER2+) and/or hormone receptor–positive (HR+) advanced breast cancer. Experimental Design: Patients with measurable tumors and progression after chemotherapy and HER2 and/or HR-targeted agents in adjuvant or metastatic settings (maximum of two prior metastatic setting regimens) received twice daily dasatinib. Primary endpoint was Response Evaluation Criteria in Solid Tumors–defined response rate. Secondary endpoints included toxicity and limited pharmacokinetics. Results: Seventy patients (55 years median age) were treated, 83% of HER2+ patients had received prior HER2-directed therapy, and 61% of HR+ patients had received prior endocrine therapy in the advanced setting. Dasatinib starting dose was reduced from 100 to 70 mg twice daily to limit toxicity. Median therapy duration was 1.8 months in both dose groups and most discontinuations were due to progression. Of 69 evaluable patients, three had confirmed partial responses and six had stable disease for 16 weeks or more (disease control rate = 13.0%); all nine of these tumors were HR+ (two were also HER2+). The most common drug-related toxicities were gastrointestinal complaints, headache, asthenia, and pleural effusion. Grade 3–4 toxicity occurred in 37% of patients and was comparable between doses; drug-related serious adverse events were less frequent with 70 mg twice daily than 100 mg twice daily. Conclusion: Limited single-agent activity was observed with dasatinib in patients with advanced HR+ breast cancer. Clin Cancer Res; 17(21); 6897–904. ©2011 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760 · cited 2×
“Hematologic toxicity was noted during dasatinib treatment of CML (17) but was not observed at a high frequency in patients with breast cancer.”
Huang, F., Reeves, K., Han, X., Fairchild, C., Platero, S., Wong, T. W., Lee, F., Shaw, P., & Clark, E. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3633 · Cited by 344 · cited 2×
“Preclinical studies, published after initiation of the current clinical study, suggest that basal-like TNBC may have preferential sensitivity to SRC inhibition (22, 23).”
Demetri, G. D., Lo Russo, P., MacPherson, I. R. J., Wang, D., Morgan, J. A., Brunton, V. G., Paliwal, P., Agrawal, S., Voi, M., & Evans, T. R. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0224 · Cited by 150
Cited by
Steeg, P. S. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.25 · Cited by 1,363
Targeting Src family kinases in anti-cancer therapies: turning promise into triumph
Zhang, S., & Yu, D. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.11.002 · Cited by 319
Src Family Kinases as Therapeutic Targets in Advanced Solid Tumors: What We Have Learned So Far
Martellucci, S., Clementi, L., Sabetta, S., Mattei, V., Botta, L., & Angelucci, A. (2020) · Cancers · doi:10.3390/cancers12061448 · Cited by 139
“II none PR = 4% PR = 100% (HER2 + ER+) 100 mg twice daily reduced to 70 mg twice daily 2011 [143]”
Translational evidence on the role of Src kinase and activated Src kinase in invasive breast cancer
Elsberger, B. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.12.009 · Cited by 54
Metadata
- Authors
- Mayer, E. L., Baurain, J.-F., Sparano, J., Strauss, L., Campone, M., Fumoleau, P., Rugo, H., Awada, A., Sy, O., & Llombart-Cussac, A.
- Venue
- Clinical Cancer Research
- Published
- 2011-10-31
- Volume
- 17
- Issue
- 21
- Pages
- 6897-6904
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2156902552
- Cited by
- 105
- References
- 3
- FWCI
- 9.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor–Positive Breast Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-11-0070
- The paper
- Mayer, E. L., Baurain, J.-F., Sparano, J., Strauss, L., Campone, M., Fumoleau, P., Rugo, H., Awada, A., Sy, O., & Llombart-Cussac, A. (2011). A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor–Positive Breast Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-11-0070
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.